Skip to main content

YI · 111, Inc. · Metrics

Track YI — free
$2.51 -0.28 (-9.99%) At close · Nov 19 Q4 2024 earnings call transcript
Market Cap
$22.08M
Shares
8.80M
Volume · Nov 19 10.2K Avg daily vol (3M) 15.76K

YI metrics

49 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.51
Market cap
$22.08M

Price action

23 metrics
Price change (1W)
-11.9%
Price change (30D)
-20.3%
Price change (3M)
-27.0%
Price change (6M)
-54.4%
Price change (YTD)
-2.0%
Price change (1Y)
-33.9%
Trailing year
Price change (5Y)
-48.2%
52-week high
$8.38
52-week low
$2.51
Change from 52-week high
-70.0%
Change from 52-week low
+0.0%
Annualized volatility
91.3%
Annualized volatility (3M)
54.9%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.4
RSI (14D)
24.2
Price vs SMA 50
-20.4%
Price vs SMA 200
-48.8%
Avg volume (3M)
15,760
Relative volume
0.7
Average dollar volume
$51,279

Company

3 metrics
Sector
Healthcare
Industry
Medical Distribution
Shares outstanding
8.80M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2024-12-31

Profitability

9 metrics
Gross margin
5.8%
Operating margin
0.0%
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
-12.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.3%
Year over year · more shares
Revenue CAGR (3Y)
-2.4%
Revenue CAGR (5Y)
+8.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
—
Debt / equity
—
Current ratio
1.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$73.07M
Total assets
$314.63M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
11
13F filer change QoQ
+3
Institutional ownership
0.5%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+24.3%
Holder tenure
9.9
Price vs estimated holder cost
-30.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
41 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$22,702
Insider-sentiment score
34 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1738906 CUSIP 68247Q201 13F (30d) 11 filings 11 filers Visit website Investor relations